Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.

Autor:	Moreno-Arrones OM; Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Electronic address: o.m.m.arrones@gmail.com., Béa-Ardebol S; Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Mayo-Martinez F; Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain., Pérez-Pastor G; Department of Dermatology, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Torres-Navarro I; Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Bonfill-Ortí M; Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Deza G; Department of Dermatology, Hospital del Mar, Barcelona, Spain., Ruiz-Salas V; Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Masferrer E; Dermatology Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain., Feal C; Dermatology Department, Hospital de Pontevedra, Galicia, Spain., Turrión-Merino L; Dermatology Department, Hospital Puerta de Hierro, Madrid, Spain., Toll A; Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain., Yébenes M; Department of Dermatology, Consorci Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain., Galiano-Mejías S; Department of Dermatology, Hospital Infanta Leonor, Madrid, Spain., Jaka A; Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain., Ferrandiz-Pulido C; Department of Dermatology, Hospital Universitari Vall d'Hebron, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Florez A; Dermatology Department, Hospital de Pontevedra, Galicia, Spain., Hernández-Hernández N; Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Fernández-de-Misa R; Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Rios-Buceta L; Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Sanmartin O; Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
Jazyk:	English; Spanish; Castilian
Zdroj:	Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2023 Jul-Aug; Vol. 114 (7), pp. 565-571. Date of Electronic Publication: 2023 Apr 23.
DOI:	10.1016/j.ad.2023.04.022
Abstrakt:	Background: Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. Objective: To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile. Methods: We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected. Results: A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24h and 48h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. Conclusion: Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice. (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu